Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $600
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh has maintained an 'Outperform' rating on United Therapeutics and raised the price target from $575 to $600.
October 31, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reaffirmed its 'Outperform' rating for United Therapeutics and increased the price target to $600, indicating confidence in the company's future performance.
The increase in price target from $575 to $600 by Oppenheimer suggests a positive outlook on United Therapeutics' future performance. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100